Ken Rice

Title: Ken Rice: Innovator in Serine-Threonine Kinase Modulation

Introduction

Ken Rice is a notable inventor based in San Rafael, California. With a focus on advancing the field of biochemistry, he has successfully secured a patent that contributes to the treatment of immunological, inflammatory, and proliferative diseases.

Latest Patents

Ken Rice is credited with a patent for “[1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators.” This invention details compounds that inhibit kinases, particularly focusing on p70S6 kinases and Akt-1 and Akt-2 kinases. It discusses the modulation of protein kinase enzymatic activity which influences critical cellular activities such as proliferation, differentiation, and programmed cell death. This innovation is significant in the treatment of diseases affected by kinase receptor signal transduction pathways.

Career Highlights

Ken Rice's contributions are exemplified through his innovative work with Exelixis, Inc., a biopharmaceutical company known for its commitment to developing innovative cancer therapies. His expertise in kinase modulation and the formulation of bioactive compounds highlight his significant role in pharmaceutical research and development.

Collaborations

Ken collaborates with esteemed colleagues, including Erick Wang and Moon Jung Kim. Together, they share a mission to enhance therapeutic strategies that leverage kinase modulation, further advancing the scope of their work in biochemistry and molecular medicine.

Conclusion

Ken Rice's innovative spirit and dedication to transforming the treatment landscape for various diseases through his patent-registered invention underline his importance in the field. His work with Exelixis, Inc. and collaborative efforts with fellow researchers continue to pave the way for significant advancements in medical science.